Fedratinib Hydrochloride and Tadalafil Tablets (Pulmonary Hypertension)
Determining the interaction of Fedratinib Hydrochloride and Tadalafil Tablets (Pulmonary Hypertension) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tadalafil should be considered. MANAGEMENT: Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone. Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours). References "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of tadalafil should be considered.
MANAGEMENT: Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone. Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).
- "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
Generic Name: tadalafil
Brand name: Adcirca, Cialis, Alyq
Synonyms: Tadalafil
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib Hydrochloride-Tafamidis
- Fedratinib Hydrochloride-Tafamidis, Tafamidis Meglumine
- Fedratinib Hydrochloride-Tafenoquine
- Fedratinib Hydrochloride-Tafenoquine (Malaria Prevention)
- Fedratinib Hydrochloride-Tafenoquine (Prevention of Malaria Relapse)
- Fedratinib Hydrochloride-Tafenoquine Succinate (Arakoda)
- Tadalafil Tablets (Pulmonary Hypertension)-Feiba
- Tadalafil Tablets (Pulmonary Hypertension)-Feiba NF
- Tadalafil Tablets (Pulmonary Hypertension)-Feiba VH Immuno
- Tadalafil Tablets (Pulmonary Hypertension)-Feiba-VH
- Tadalafil Tablets (Pulmonary Hypertension)-Felbamate
- Tadalafil Tablets (Pulmonary Hypertension)-Felbamate Oral Suspension